Intervention

B/F/TAF

ClinicalTrials.gov intervention label

Clinical trials14

Recruiting0

Common conditions6

Lead sponsors shown6

Clinical trials

14 shown

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIVNCT07055451 · 2025-08-12

ACTIVE_NOT_RECRUITING

Good-first: B/F/TAF As First-line ARTNCT06619288 · 2024-07-01

The Antiretroviral Speed Access Program Switch (ASAP-Switch) StudyNCT06375304 · 2024-05-01

NOT_YET_RECRUITING

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVNCT05052996 · 2021-10-05

ACTIVE_NOT_RECRUITING

Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of AgeNCT05147740 · 2021-07-01

Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed AdultsNCT04311957 · 2020-09-01

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIVNCT04143594 · 2019-11-22

Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third TrimestersNCT03960645 · 2019-06-28

B/F/TAF Switch Study for HIV-HBV CoinfectionNCT03797014 · 2019-04-30

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected AdultsNCT03739866 · 2018-11-26

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically SuppressedNCT03110380 · 2017-06-12

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT02607930 · 2015-11-13

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT02607956 · 2015-11-11

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsNCT02397694 · 2015-03-23

Common conditions

HIV-1-infection7 HIV-1 Infection5 Antiretroviral Therapy1 Hepatitis B1 HIV Infection1 HIV Infections1

Leading sponsors

Gilead Sciences9 Affiliated Hospital of Nantong University1 Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic1 McGill University Health Centre/Research Institute of the McGill University Health Centre1 Tulika Singh, MD1 University of Maryland, Baltimore1

Trial status mix

COMPLETED8

UNKNOWN3

ACTIVE_NOT_RECRUITING2

NOT_YET_RECRUITING1

Phase mix

PHASE44

PHASE13

PHASE23

PHASE33

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.